Patients Discontinuing Anti-Obesity Jabs Regain Weight at a Quadrupled Rate Than People Using Diet and Exercise

Fresh analysis indicates that people who come off new GLP-1 drugs like semaglutide or tirzepatide may regain lost weight at a significantly accelerated pace than those who halt conventional lifestyle regimens.

Research printed in a major medical journal demonstrates that while overweight people can lose a large proportion of their body weight while using the jabs, the weight comes back at an estimated rate of 0.8 kg per month upon discontinuation.

"Individuals using such treatments should be cognizant of the danger of quick rebound weight gain when the medication concludes," stated lead investigator Dr. Susan Jebb.

Such speed of regain suggests a return to pre-treatment mass within about 18 months.

Analyzing Treatments

The study, which reviewed dozens of studies involving thousands of participants, contrasted the results of the injectable medications with conventional dieting.

The team point out that people who shed pounds through diet and exercise usually have a slower weight regain—perhaps 0.1 kg a month—after stopping.

The Reason for the Fast Rebound

Doctors believe the mechanism of the jabs explains the accelerated regain.

These medications imitate a natural hormone called GLP-1, which moderates hunger.

"Long-term administration of GLP-1 levels several times higher than the body's typical production might result in the system to produce less of its endogenous hormone, and may also lessen responsiveness to its effects," noted Dr. Adam Collins, a dietetics researcher.

"Discontinuation of this hormone supplement leads to appetite is no longer kept in check, making overeating a significant risk."

A Lifelong Issue?

Health authorities suggest the jabs for individuals with obesity-related medical conditions, accompanied by prescribed lifestyle changes.

A number of clinicians contend that, considering the high risk of weight regain, the treatment is often life-long.

This opinion is reinforced by drug manufacturers, who say that the findings "highlight the chronic character of excess weight," akin to managing conditions like hypertension.

User Accounts

Users who have discontinued the jabs describe a sudden return of hunger.

"It was like a trigger that goes on and I was suddenly extremely hungry," said a patient.

This challenge is compounded if patients have not developed lasting lifestyle or habit changes during treatment.

Widespread Use

Recent estimates indicate that millions of people in the UK have used these injections in the past year, with demand continuing to grow.

• Adoption is greater among women compared to males.
• The 40s and 50s demographic shows the greatest level of interest.
• A large proportion access the drugs through private healthcare rather than public health services.

Finally, researchers caution that while GLP-1 drugs are potent tools for weight loss, they are not a standalone cure and lasting health benefits hinges on combined lifestyle management.